Is Moderna Stock a Buy Now?
Moderna (NASDAQ: MRNA) is a healthcare business in transition. Expectations are lower this year as the government isn't going to be loading up on the company's COVID-19 vaccine anymore.
That doesn't mean sales will evaporate, but investors do need to brace for a new reality for the business. Year to date, Moderna's shares have fallen 22% even as the S&P 500 has shown signs of life, rising 3%.
Has Moderna become a bad-news buy, or are shares of the healthcare stock likely to decline even further?
Source Fool.com
